BSE filing, NSE: VEDAVAAG. Summary written from the filing by ALFA Finder's alert engine.
Vedavaag Systems Ltd: key numbers
- Share price
- ₹19.65
- Market cap
- ₹46.11 Cr
- Revenue (annual)
- ₹128.5 Cr
- Net profit (annual)
- ₹5.20 Cr
- P/E (TTM)
- 11.1×Sector 23.0×
- Promoter holding
- 35.16%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vedavaag Systems Ltd
All →Vedavaag Systems Other Announcement
VEDAVAAG Systems Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, complying with regulatory disclosure requirements.
Vedavaag Systems Capital Structure Change
Vedavaag Systems Limited will invest Rs. 0.75 Crore in its wholly-owned subsidiary, Vedavaag Financial Insurance Broking Services Private Limited, through a rights issue.
- Value
- ₹0.75 Cr
Vedavaag Systems Regulatory Approval
Vedavaag Systems' subsidiary, Vedavaag Financial Insurance Broking Services, received in-principle approval from IRDAI to operate as a Direct Insurance Broker.
Vedavaag Systems Annual General Meeting
Vedavaag Systems Limited conducted its 28th Annual General Meeting on September 30, 2026. Shareholders adopted the FY2026 audited financial statements and re-appointed Mr. Ananth Jonnavittula as Director.
Vedavaag Systems Business Update
Vedavaag Systems' board approved a capital investment in its wholly owned subsidiary, Vedavaag Financial Insurance Broking Services. Details will be disclosed upon receipt of regulatory approvals.
Vedavaag Systems Annual General Meeting
Vedavaag Systems Limited announced its 28th Annual General Meeting is scheduled for September 30, 2026. The board approved the AGM notice, directors' report, and member register closure.
Other regulatory approval announcements
All →Hikal Regulatory Approval
Hikal's Bengaluru API facility received a Swissmedic GMP Certificate of Compliance. The certification supports wider access to European and other regulated markets.
Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
RNFI Services Regulatory Approval
RNFI received RBI no-objection to acquire control of Smart Payment Solutions Private Limited. Remaining tranches may proceed, but no transaction value is disclosed.
Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.